Institute Of Biomedical Research Stock Price, News & Analysis
Company Description
Institute Of Biomedical Research (OTC Link: MRES) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $18.4M.
MRES stock has declined 91.1% over the past year. Shares last traded at $0.0019.
This page provides a comprehensive overview of MRES stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Institute Of Biomedical Research (MRES) stock last traded at $0.0019. Over the past 12 months, the stock has lost 91.1%. At a market capitalization of $18.4M, MRES is classified as a micro-cap stock with approximately 2.4B shares outstanding.
Latest News
Institute Of Biomedical Research has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 6 with negative movement. Key topics include acquisition. View all MRES news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Institute Of Biomedical Research (MRES) currently stands at 24.5 thousand shares, up 1000.0% from the previous reporting period. Over the past 12 months, short interest has increased by 868.6%.
Days to Cover History
Days to cover for Institute Of Biomedical Research (MRES) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
MRES Company Profile & Sector Positioning
Institute Of Biomedical Research (MRES) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing MRES often look at related companies in the same sector, including Rapid Dose Thera (RDTCF), Finch Therapeutics Group, Inc. (FNCH), Biomind Labs Inc (BMNDF), Pharmather Holdings Ltd (PHRRF), and Oncotelic Therapeutics Inc (OTLC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MRES's relative position within its industry.